Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Fosun Long March's COVID-19 Test Approved in China

publication date: Mar 27, 2020
 | 
author/source: Richard Daverman, PhD

Shanghai Fosun Long March Medical Science, a wholly-owned in vitro diagnostics subsidiary of Fosun Pharma (SHA: 600196; HK: 02196), was granted emergency approval to launch its novel coronavirus nucleic acid detection kit in China. The company said it based the test on its speedy test reagents for Type A&B flu and common respiratory viruses. Earlier this month, Fosun Long March received CE certification to market the test in Europe.

Fosun said the kit offers qualitative detection of novel coronavirus ORF1ab, N and E gene targets. It has the ability to complete the detection of 96 samples within two hours via fast nucleic acid extraction instrument and extraction reagents. In addition, as an automated test, the kit lowers the risk of operator infection, reduces the risk of cross contamination in the laboratory and improves detection efficiency.

See our other articles on Fosun Pharma.

Disclosure: none.

 


 

Share this with colleagues:

 

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China